Endre-Botond Gagyi, Brigitta Teutsch, Dániel Sándor Veres, Dániel Pálinkás, Nóra Vörhendi, Klementina Ocskay, Katalin Márta, Péter Jenő Hegyi, Péter Hegyi, Bálint Erőss
{"title":"急性胰腺炎后复发和慢性胰腺炎的发病率：系统回顾和荟萃分析。","authors":"Endre-Botond Gagyi, Brigitta Teutsch, Dániel Sándor Veres, Dániel Pálinkás, Nóra Vörhendi, Klementina Ocskay, Katalin Márta, Péter Jenő Hegyi, Péter Hegyi, Bálint Erőss","doi":"10.1177/17562848241255303","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Acute pancreatitis (AP) has a high incidence, and patients can develop recurrent acute pancreatitis (RAP) and chronic pancreatitis (CP) after AP.</p><p><strong>Objectives: </strong>We aimed to estimate the pooled incidence rates (IRs), cumulative incidences, and proportions of RAP and CP after AP.</p><p><strong>Design: </strong>A systematic review and meta-analysis of studies reporting the proportion of RAP and CP after AP.</p><p><strong>Data sources and methods: </strong>The systematic search was conducted in three (PubMed, EMBASE, and CENTRAL) databases on 19 December 2023. Articles reporting the proportion of RAP or CP in patients after the first and multiple episodes of AP were eligible. The random effects model was used to calculate the pooled IR with 95% confidence intervals (CIs). The <i>I</i> <sup>2</sup> value assessed heterogeneity. The risk of bias assessment was conducted with the Joanna Briggs Institute Critical Appraisal Tool.</p><p><strong>Results: </strong>We included 119 articles in the quantitative synthesis and 29 in the IRs calculations. Our results showed that the IR of RAP in adult patients after AP was 5.26 per 100 person-years (CI: 3.99-6.94; <i>I</i> <sup>2</sup> = 93%), while in children, it was 4.64 per 100 person-years (CI: 2.73-7.87; <i>I</i> <sup>2</sup> = 88%). We also found that the IR of CP after AP was 1.4 per 100 person-years (CI: 0.9-2; <i>I</i> <sup>2</sup> = 75%), while after RAP, it increased to 4.3 per 100 person-years (CI: 3.1-6.0; <i>I</i> <sup>2</sup> = 76%). The risk of bias was moderate in the majority of the included studies.</p><p><strong>Conclusion: </strong>Our results showed that RAP affects many patients with AP. Compared to patients with the first AP episode, RAP leads to a threefold higher IR for developing CP.</p><p><strong>Trial registration: </strong>Our protocol was registered on PROSPERO (CRD42021283252).</p>","PeriodicalId":48770,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"17 ","pages":"17562848241255303"},"PeriodicalIF":3.9000,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11179553/pdf/","citationCount":"0","resultStr":"{\"title\":\"Incidence of recurrent and chronic pancreatitis after acute pancreatitis: a systematic review and meta-analysis.\",\"authors\":\"Endre-Botond Gagyi, Brigitta Teutsch, Dániel Sándor Veres, Dániel Pálinkás, Nóra Vörhendi, Klementina Ocskay, Katalin Márta, Péter Jenő Hegyi, Péter Hegyi, Bálint Erőss\",\"doi\":\"10.1177/17562848241255303\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Acute pancreatitis (AP) has a high incidence, and patients can develop recurrent acute pancreatitis (RAP) and chronic pancreatitis (CP) after AP.</p><p><strong>Objectives: </strong>We aimed to estimate the pooled incidence rates (IRs), cumulative incidences, and proportions of RAP and CP after AP.</p><p><strong>Design: </strong>A systematic review and meta-analysis of studies reporting the proportion of RAP and CP after AP.</p><p><strong>Data sources and methods: </strong>The systematic search was conducted in three (PubMed, EMBASE, and CENTRAL) databases on 19 December 2023. Articles reporting the proportion of RAP or CP in patients after the first and multiple episodes of AP were eligible. The random effects model was used to calculate the pooled IR with 95% confidence intervals (CIs). The <i>I</i> <sup>2</sup> value assessed heterogeneity. The risk of bias assessment was conducted with the Joanna Briggs Institute Critical Appraisal Tool.</p><p><strong>Results: </strong>We included 119 articles in the quantitative synthesis and 29 in the IRs calculations. Our results showed that the IR of RAP in adult patients after AP was 5.26 per 100 person-years (CI: 3.99-6.94; <i>I</i> <sup>2</sup> = 93%), while in children, it was 4.64 per 100 person-years (CI: 2.73-7.87; <i>I</i> <sup>2</sup> = 88%). We also found that the IR of CP after AP was 1.4 per 100 person-years (CI: 0.9-2; <i>I</i> <sup>2</sup> = 75%), while after RAP, it increased to 4.3 per 100 person-years (CI: 3.1-6.0; <i>I</i> <sup>2</sup> = 76%). The risk of bias was moderate in the majority of the included studies.</p><p><strong>Conclusion: </strong>Our results showed that RAP affects many patients with AP. Compared to patients with the first AP episode, RAP leads to a threefold higher IR for developing CP.</p><p><strong>Trial registration: </strong>Our protocol was registered on PROSPERO (CRD42021283252).</p>\",\"PeriodicalId\":48770,\"journal\":{\"name\":\"Therapeutic Advances in Gastroenterology\",\"volume\":\"17 \",\"pages\":\"17562848241255303\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2024-06-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11179553/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Gastroenterology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/17562848241255303\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17562848241255303","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
Incidence of recurrent and chronic pancreatitis after acute pancreatitis: a systematic review and meta-analysis.
Background: Acute pancreatitis (AP) has a high incidence, and patients can develop recurrent acute pancreatitis (RAP) and chronic pancreatitis (CP) after AP.
Objectives: We aimed to estimate the pooled incidence rates (IRs), cumulative incidences, and proportions of RAP and CP after AP.
Design: A systematic review and meta-analysis of studies reporting the proportion of RAP and CP after AP.
Data sources and methods: The systematic search was conducted in three (PubMed, EMBASE, and CENTRAL) databases on 19 December 2023. Articles reporting the proportion of RAP or CP in patients after the first and multiple episodes of AP were eligible. The random effects model was used to calculate the pooled IR with 95% confidence intervals (CIs). The I2 value assessed heterogeneity. The risk of bias assessment was conducted with the Joanna Briggs Institute Critical Appraisal Tool.
Results: We included 119 articles in the quantitative synthesis and 29 in the IRs calculations. Our results showed that the IR of RAP in adult patients after AP was 5.26 per 100 person-years (CI: 3.99-6.94; I2 = 93%), while in children, it was 4.64 per 100 person-years (CI: 2.73-7.87; I2 = 88%). We also found that the IR of CP after AP was 1.4 per 100 person-years (CI: 0.9-2; I2 = 75%), while after RAP, it increased to 4.3 per 100 person-years (CI: 3.1-6.0; I2 = 76%). The risk of bias was moderate in the majority of the included studies.
Conclusion: Our results showed that RAP affects many patients with AP. Compared to patients with the first AP episode, RAP leads to a threefold higher IR for developing CP.
Trial registration: Our protocol was registered on PROSPERO (CRD42021283252).
期刊介绍：
Therapeutic Advances in Gastroenterology is an open access journal which delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of gastrointestinal and hepatic disorders. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in gastroenterology and related disciplines, providing an online forum for rapid dissemination of recent research and perspectives in this area.
The editors welcome original research articles across all areas of gastroenterology and hepatology.
The journal publishes original research articles and review articles primarily. Original research manuscripts may include laboratory, animal or human/clinical studies – all phases. Letters to the Editor and Case Reports will also be considered.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
